How to Determine Whether or Not a SCT is Successful
How to Determine Whether or Not a SCT is Successful image
Mar 03, 2022 / 02:00PM - 03:00PM EST
Stem Cell Transplant Chapter

Event Description

Many patients understandably experience intense frustration when their stem cell transplant doesn't put them into full remission. Others feel real disappointment when after such an intense procedure, their labs still don't reflect MRD negativity. Dr. Guido Tricot joins the Stem Cell Transplant Chapter to share his thoughts on what constitutes a stem cell transplant procedure as "successful" or "unsuccessful". Come with your questions for Dr. Tricot and learn together with our Chapter.

Schedule & Agenda

person
Introduction
02:00PM
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Guido Tricot.
person
Presentation
02:05PM
Dr. Guido Tricot
Dr. Tricot shares his thoughts on what constitutes a stem cell transplant procedure as "successful" or "unsuccessful".
person
Questions and Answers
02:35PM
Audience
Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Dr. Guido Tricot
Dr. Guido Tricot

Dr. Tricot's most recent clinical studies focus on not only attacking myeloma cells but also the microenvironment that supports the survival and growth of myeloma cells. His work aims at finding treatments that are non-cross-resistant with current chemotherapy and therefore can eradicate the drug-resistant myeloma cells. His work on detailed genetics of myeloma cells should allow individualized therapies to ensure the greatest efficacy, while minimizing toxicity. Over the last 15 years, the median survival for patients newly diagnosed with myeloma has, in large part due to this work, increased from 2.5 to more than 10 years. The complete remission rate has increased from 5% to 80% and one third of all patients are still in complete remission at 10 years. He received his medical degree from Catholic University of Leuven and has been in practice for more than 20 years.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811